Beleave Inc. (CSE:BE) (OTCQX:BLEVF) (“Beleave” or the “Company”) would like to commend the outstanding leadership, tenacity, and bravery of the Canadian government in passing Bill C-45 into law. As the first G7 country to legalize cannabis, this forever reaffirms Canada’s reputation as a forward-thinking nation to live and do business in.

Beleave continues to build its distribution to be well-positioned to meet the demand of the recreational and medical cannabis markets.  The Company’s greenhouse expansion in Hamilton is well underway while it is continuing to expand its network of medical clinics by way of the Medi-Green brand and its recreational retail stores through a newly-granted retail license in Saskatchewan.  The Saskatchewan license is the first of many proposed retail locations the Company plans to roll out in Canada which will offer a diverse range of products available both online and in store.


“Beleave has had a great year so far,” said Beleave’s CEO, Andrew Wnek. “This milestone has been a long-time coming and now that it’s here we can celebrate another win and move forward. We feel the comprehensive regulatory framework for adult cannabis use is fair and will work to eliminate the black market, protect our youth, and remain mindful of public health and safety.”

The Company released news yesterday announcing its global expansion into Colombia, a jurisdiction believed to be right behind Canada on the path to legalized and regulated cannabis. The Company plans to strike more deals in a well thought out and strategic manner advantageous to shareholder growth without paying the high premiums currently associated with todays cannabis marketplace.

“We’ve raised roughly $20 million in the last several months, strengthening the company’s balance sheet to capitalize on industry opportunities. We thank our investors for their continued confidence and support,” commented Bojan Krasic, Beleave’s Director and CFO. “Also, we acknowledge the diligence of our amazing team. Their hard work, dedication, and innovation has prepared us like never before for this next chapter in Beleave’s story.”

About Beleave

Beleave is a biotech company and the Company’s wholly-owned subsidiary Beleave Kannabis Corp. is licensed to cultivate and sell medical cannabis and produce cannabis oils and extracts pursuant to Health Canada’s Access to Cannabis for Medical Purpose Relations. Beleave has been selected to operate in Saskatchewan’s upcoming cannabis retail market and has developed a network of medical cannabis clinics under the Medi-Green banner. The Company has applied for various patents to broaden its strong research focused foundation.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

Click here to connect with Beleave Inc. (CSE:BE) (OTCQX:BLEVF) for an Investor Presentation.

Source: www.prnewswire.com

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf Solutions“, “OILS”, or the “Company”), Canada’s most innovative cannabis extractor, is pleased to provide the following commercial and intellectual property update:

Cannabis Extraction Agreement with White Label Producer

Keep reading... Show less

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that it has closed today its previously announced “bought deal” short form prospectus offering of units (“ Unit s ”), including the exercise in full of the over-allotment option (the “ Offering ”).

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

For more information regarding the Cowen 2020 Boston Cannabis Conference please visit: https://www.cowen.com/conferences-and-events/3rd-annual-boston-cannabis-conference/

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE:ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws

Keep reading... Show less